SMS vs. Apps for Effective Digital Health Interventions
A Field Guide for builders who keep being asked “SMS or app?” and don’t yet have a confident answer.
Estimated total read time: 30 minutes. Skim time: 90 seconds.
TLDR
Allocate by reach vs. response.
SMS for reach jobs (action outside the channel);
Apps for response jobs (structured input inside it).
Most chronic care programs need both.
The platform is never the intervention.
Platforms exist to affect what humans do beyond them: patients taking pills, clinicians titrating, care teams closing the loop.
A delivery vector, not the mechanism.
Audience decay is the SMS-vs-App economic divider.
App audiences decay continuously through uninstalls, OS push restrictions, and device churn; the reach floor surfaces only when re-engagement fails.
SMS preserves the addressable list across years through phone-number persistence.
Healthcare CAC is paid upfront, so audience decay erodes the reach floor before outcomes are measured;
Medicaid weakens this but doesn’t invalidate it.
Program adherence (actual patient behavior) is the leading indicator of clinical outcomes; engagement should be limited to a product-health metric.
Track completion at 80% (or the condition-specific equivalent).
Engagement stays on the product dashboard.
The patient heals and buyer renews on health and economic outcomes.
Those are what should drive your operational decisions and dashboards.
Combined modalities beat single-channel automation.
Across the trial record, pairing a delivery channel with a staffed action layer beats single-channel automation.
Program architecture beats channel.
Stand up regulatory compliance before launch.
Register every brand and use case with The Campaign Registry; build to the FCC treatment-purpose exemption and the CTIA floor.
Retrofitting TCPA, HIPAA, or 10DLC after launch is the most expensive architectural choice an SMS program can make.
Author’s note
For the past six years, I’ve mentored healthcare founders through NYU accelerators and public workshops that I host in New York City. The thesis behind that work has been consistent:
Only new mistakes.
VC-backed healthtech has a pattern of new builders impaling themselves upon old failure modes. Research findings stay trapped in journals. Operational lessons stay trapped inside health plans and care teams who’ve done this work for decades.
These Field Guides exist to help close that gap.
The goal is effective digital health programs: interventions that survive their unit economics, improve the outcomes enterprise buyers renew contracts on, and most importantly reduce patient suffering.
Part of my unfair advantage as a mentor is that I have operators in my network who have built and delivered care at population scale. They’ve already learned many of the expensive lessons and have generously provided their feedback and comments on this piece.
Evan Huang, developed SMS programs reaching 2% of the U.S. chronic care population, First as co-founder of CareSignal and then as CTO of Lightbeam after the acquisition.
Ramon Lizardo, MD, MBA, built the nation’s largest ED diversion company, covering 9.5M lives across 150 health plans as CEO of Tele911.
Brittany Sigler, MPH, DrPH, was a product leader across multiple population-scale outreach programs at CVS Caremark and Aetna.
This field guide distills lessons from 30 years of clinical, operational, regulatory, and behavioral literature surrounding healthcare communication systems. It is not clinical, legal, or compliance advice.
This document was developed using Claude Cowork + custom skills as my primary collaborator, with Gemini, ChatGPT, and Perplexity providing redteam support. My use of AI is loud and proud. The arguments and conclusions are mine.
Vadim Gordin.
Only new mistakes.
© 2026 Vadim Gordin. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
Contents
The piece is organized in three parts. Each can be read on its own.
The conceptual frame: why the channel choice is the wrong unit of analysis,
the six-layer causal chain from message-delivered to therapeutic and economic outcomes that every digital chronic care program runs,
the economics of reachability between SMS and Apps, and
how scaffolding can dramatically improve retention and engagement rates.
Action beyond the platform is the actual intervention.
Part 2. What the Evidence Supports.
The five clinical truths the literature supports,
where apps and SMS each win on a per-task basis,
what is the cost and consequence of platform failures, and
how LLMs fit inside the operational stack.
How to measure and instrument an effective program and
common failure modes in both commercial and research programs.
Will me compliance architecture survive scrutiny or create liability?
The appendix is intended to be a reference tool rather than something to read end-to-end
All 75+ cited clinical trials by topic and specialty.
If you’re building a renal care or ob/gyn platform for Medicaid and want to read up on how previous SMS interventions have performed, the appendix is your on-ramp.
The 3 major regulatory regimes governing SMS in the US organized into an actionable reference for builders.
